Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines - Wikidata - awgldk - TriplyDB

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

http://www.wikidata.org/entity/Q33255244

about

Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity Computational Design of the Affinity and Specificity of a Therapeutic T Cell Receptor Age-dependent tolerance to an endogenous tumor-associated antigen.T-cell antagonism by short half-life pMHC ligands can be mediated by an efficient trapping of T-cell polarization toward the APC A role for rebinding in rapid and reliable T cell responses to antigen Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity.Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.The Goldilocks model for TCR-too much attraction might not be best for vaccine design Attenuated T cell responses to a high-potency ligand in vivo.Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time.Antigen potency and maximal efficacy reveal a mechanism of efficient T cell activation.T cell avidity and tumor immunity: problems and solutions Specific increase in potency via structure-based design of a TCR.Translating tumor antigens into cancer vaccines Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses.Vaccination of mice with baculovirus-infected insect cells expressing antigenic proteins.Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.TCR hypervariable regions expressed by T cells that respond to effective tumor vaccines.Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens.SHP-1 phosphatase activity counteracts increased T cell receptor affinity.Control of T cell antigen reactivity via programmed TCR downregulation.T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy Mobilizing the low-avidity T cell repertoire to kill tumors.Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology.Architecture of a minimal signaling pathway explains the T-cell response to a 1 million-fold variation in antigen affinity and dose.Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system.Improving T cell responses to modified peptides in tumor vaccines T cell sensitivity and the outcome of viral infection.Molecular insights for optimizing T cell receptor specificity against cancer.Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.Effect of multiple genetic polymorphisms on antigen presentation and susceptibility to Mycobacterium tuberculosis infection.In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.Accumulation of dynamic catch bonds between TCR and agonist peptide-MHC triggers T cell signaling.Dynamical footprint of cross-reactivity in a human autoimmune T-cell receptor.Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms.

P2860

Q26774669-EFDA6EAF-5713-46C9-BCBF-D62EC5F26AE1 Q27680213-7316EAC4-8BBC-4DA9-9466-6924377020C8 Q27681832-431C2017-5044-4E09-9D60-B678E54BAA04 Q30439993-6330B9EF-88CB-45EC-BB1F-0DBA012E120D Q30492783-B5C0F641-89B6-43A3-93E2-B16062F8E15D Q30946361-92EE403E-A9A2-4D98-8B66-78E424E2751C Q33311675-57B347A7-1772-4FA3-9746-C8756160E961 Q33529578-5553C25A-2E5B-46C6-AF79-72A78F195B3F Q33698006-5DFFC0CC-5AC5-4FF2-8261-34FC4726D015 Q33698019-D9EDEB7A-E807-4F69-A723-518D5644B3F5 Q33821395-BD0C980E-E593-4650-BD2E-E8D1D9C98098 Q34086610-B5F52DD5-3BA6-4447-A0C5-7744D27DFD4C Q34115960-5C00601D-A99B-4D44-BB7D-3CF5F095A8B7 Q34383054-F1CDF1F6-E854-4492-9695-00ECC97FFA9B Q34484042-D20A6AA1-6013-4C85-8F32-915766B17657 Q35012363-F8BEF00B-A83C-4E7E-8C46-6FC0F65450EA Q35533181-9CB685AF-3B8F-490C-9289-47BAE4A55FF1 Q35906719-0EC56FB7-9714-44D5-AEEE-BFAA92E5F538 Q35932542-8D7562DC-791E-47C4-AC13-4DC61D89140E Q36080586-EC3083DD-A452-4639-9E65-9295723A5D1D Q36137249-05AE982D-367B-45B1-80DF-19CB637F1F64 Q36510860-6478C72D-AD88-4A4D-9DCD-2FA084C89CD3 Q36638160-B0EA2620-ABC9-400F-9C07-C115FA960D35 Q36717167-E633350C-C455-48F1-8E83-099370F58CDB Q36799229-B3D1C360-5414-46F7-8CDA-C447C7955BA3 Q36891310-DC47C923-7C3B-4A68-A2F7-BBA66F3E87AE Q36977064-9D16A946-CFE4-4BF0-85D5-3304905844F1 Q37379865-5076EA8B-D8CC-4EC0-952E-1D3E2960256A Q37439832-8B002709-D66C-4C48-89B8-52284CDCCEE3 Q37494158-64FA83A6-43BF-400B-9686-306A3AFA5194 Q37614812-D17BBDC9-CFCE-4D9A-8033-5757821F420B Q37634253-AB8F48ED-1A13-4541-BECE-56D56E283440 Q37646853-EA033838-8FC1-41EA-AA53-366C1F302C7C Q38117139-8CF6BAD8-2356-4D99-9230-B0AF37B03AFA Q39637191-D67D2A75-580F-41FE-A312-657263D6F254 Q39758413-9B31FD35-155C-42D3-8DE6-5A8AACEFEF00 Q40188864-8D49DA74-74BF-4E42-ABFE-636A6406FE3A Q41769969-E129E0D8-AC8D-4482-8CB2-903E14FA70BD Q42321774-F1AFE546-3476-4354-9737-ECFF8E26550E Q47113506-59F84CF1-E791-46A2-8B4C-9DDCAD5FC568

P2860

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

http://www.wikidata.org/entity/Q33255244

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

@ast

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

@en

type

label

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

@ast

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

@en

prefLabel

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

@ast

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

@en

P1433

Q33255244-C564A30C-E06A-4DCA-83E8-BD23D5E38666

P1476

Q33255244-540027C9-C232-4BC6-97D2-6AB06849367B

P2093

Q33255244-1DF576BE-9EEF-4FDF-A139-05180B9EBFB0

Q33255244-3112336B-CB90-4E17-B78F-9C08AC8E1625

Q33255244-8F70DF08-06F0-485F-8520-29B156A0B024

Q33255244-964312D2-A3E6-4D5E-AB65-23AC74F0C7AA

Q33255244-D04CD251-F243-42D6-9947-182DC2769054

Q33255244-F96B6BEE-FFE6-4324-8AF4-CB635469B050

P2860

Q33255244-0AEAF643-1001-4D3A-8288-8828AD57F5B7

Q33255244-0DF91D8A-8136-414B-AF46-CE26E1E8C669

Q33255244-0F0DA7F2-37CA-4202-91E5-C6F722107DFE

Q33255244-17417C1B-1C80-4DCE-A1C2-06DE35F37EF4

Q33255244-18BC3A74-B643-4F20-A56E-9F457A79A614

Q33255244-242068BE-D61E-4072-A615-EBFF803CBA6B

Q33255244-251DE630-2E19-419F-B2AB-9361F8A67BDC

Q33255244-2D8B5E5E-9B1E-4AFB-BDB4-4E7182BF95B5

Q33255244-31038E2C-1E04-45A3-AFC1-B43FB4D4E717

Q33255244-3414BAC2-17DC-4F98-AD6B-2C4B0284C088

P304

Q33255244-2E331DBF-5BFB-4D67-98FF-3788B950CB0D

P31

Q33255244-0CD1A068-B2DE-4DDD-BDF1-28B1427B131D

P356

Q33255244-CB45EC6B-B62A-4154-B3C1-93057C7675F4

P407

Q33255244-32E9679D-7901-4D1A-AFFC-CFBD4A2F48EB

P433

Q33255244-F7D0B0DD-24D5-41C4-9404-B794CD105372

P478

Q33255244-4BACB6CB-01E5-4A62-B7F5-02A4D8B68B5A

P577

Q33255244-6057741F-FC1F-4AA2-A8F3-FAB4AB707B88

P5875

Q33255244-E60BD421-C932-486A-BD01-D0802C5B6A6A

P698

Q33255244-A99154A2-1447-43A1-A0EB-4291DD321EFF

P932

Q33255244-0B153599-CEEA-4F13-BCB0-56C04C652A9B

P356

P1433

Journal of Clinical Investigation

P1476

Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines

@en

P2093

Darcy B Wilson

http://www.w3.org/2001/XMLSchema#string

Jennifer A McWilliams

http://www.w3.org/2001/XMLSchema#string

Jill E Slansky

http://www.w3.org/2001/XMLSchema#string

Kimberly R Jordan

http://www.w3.org/2001/XMLSchema#string

Rachel H McMahan

http://www.w3.org/2001/XMLSchema#string

Steven W Dow

http://www.w3.org/2001/XMLSchema#string

P2860

Viral immune evasion due to persistence of activated T cells without effector function

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Diversity and recognition efficiency of T cell responses to cancer

Structural and functional consequences of altering a peptide MHC anchor residue

Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts

The three-dimensional structure of an H-2Ld-peptide complex explains the unique interaction of Ld with beta-2 microglobulin and peptide

Structural basis of 2C TCR allorecognition of H-2Ld peptide complexes

The roles of IFN gamma in protection against tumor development and cancer immunoediting

The three Es of cancer immunoediting

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins

P304

2543-2551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI26936

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2006-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6855269

http://www.w3.org/2001/XMLSchema#string

P698

16932807

http://www.w3.org/2001/XMLSchema#string

P932

1551931

http://www.w3.org/2001/XMLSchema#string